| 周芳怡,凌 敏,成碧薇,吴 佳,何 静.坤复康片联合阿莫西林克拉维酸钾对慢性盆腔炎患者血液流变学、红细胞免疫功能和炎症因子的影响[J].现代生物医学进展英文版,2023,(11):2188-2191. |
| 坤复康片联合阿莫西林克拉维酸钾对慢性盆腔炎患者血液流变学、红细胞免疫功能和炎症因子的影响 |
| Effects of Kunfukang Tablet Combined with Amoxicillin Potassium Clavulanate on Hemorheology, Erythrocyte Immune Function and Inflammatory Factors in Patients with Chronic Pelvic Inflammatory Disease |
| Received:October 03, 2022 Revised:October 27, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.11.037 |
| 中文关键词: 坤复康片 阿莫西林克拉维酸钾 慢性盆腔炎 血液流变学 红细胞免疫功能 炎症因子 |
| 英文关键词: Kunfukang tablet Amoxicillin potassium clavulanate Chronic pelvic inflammatory disease Hemorheology Erythrocyte immune function Inflammatory factor |
| 基金项目:湖南省卫生健康委科研计划项目（20200786） |
|
| Hits: 656 |
| Download times: 372 |
| 中文摘要: |
| 摘要 目的：探讨坤复康片联合阿莫西林克拉维酸钾对慢性盆腔炎患者血液流变学、红细胞免疫功能和炎症因子的影响。方法：采用随机数字表法将我院2021年4月~2022年4月期间收治的98例慢性盆腔炎患者分为对照组（阿莫西林克拉维酸钾干混悬剂治疗，n=49）和研究组（坤复康片联合阿莫西林克拉维酸钾干混悬剂治疗，n=49）。对比两组症状好转时间、血液流变学、红细胞免疫功能和炎症因子水平，观察两种用药方案的安全性。结果：研究组的下腹疼痛、腰骶疼痛、白带量多、经期量多等临床症状好转时间均短于对照组（P<0.05）。研究组治疗14 d后全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原水平低于对照组（P<0.05）。研究组治疗14 d后血红细胞C3b受体花环率（RBC-C3bRR）高于对照组，免疫复合物花环率（RBC-ICR）低于对照组（P<0.05）。研究组治疗14 d后血清C反应蛋白（CRP）、白细胞介素-17（IL-17）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：坤复康片联合阿莫西林克拉维酸钾可通过改善慢性盆腔炎患者的血液流变学、炎症因子、红细胞免疫功能来改善临床症状，具有较好的临床疗效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Kunfukang tablet combined with amoxicillin potassium clavulanate on hemorheology, erythrocyte immune function and inflammatory factors in patients with chronic pelvic inflammatory disease. Methods: 98 patients with chronic pelvic inflammatory disease who were admitted to our hospital from April 2021 to April 2022 were divided into control group (amoxicillin potassium clavulanate dry suspension treatment, n=49) and study group (Kunfukang tablets combined with amoxicillin potassium clavulanate dry suspension treatment, n=49) by using random number table method.Symptom improvement time, hemorheology, erythrocyte immune function and inflammatory factor levels in the two groups were compared, and the safety of the two medication regiments were observed. Results: The clinical symptoms improvement time of lower abdominal pain, lumbosacral pain, excessive leucorrhea and many menstrual periods in the study group were shorter than those in the control group (P<0.05). After 14 days of treatment, the whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and fibrinogen levels in the study group were lower than those in the control group(P<0.05). After 14 days of treatment, the Red blood cell C3b receptor rosette rate（RBC-C3bRR） of the study group was higher than that of the control group, and the Immune complex rosette rate (RBC-ICR) was lower than that of the control group (P<0.05). Serum C-reactive protein (CRP), interleukin-17 (IL-17), tumor necrosis factor-α(TNF-α), The level of interleukin-6 (IL-6) in the study group after 14 days of treatment were lower than those of the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Kunfukang tablets combined with amoxicillin potassium clavulanate can improve clinical symptoms by improving hemorheology,erythrocyte immune function and inflammatory factor level in patients with chronic pelvic inflammatory disease, which has good clinical effect. |
|
View Full Text
View/Add Comment Download reader |
| Close |
